Chemed Executive Spencer Lee Sells 1,000 Shares for $541,040
Spencer S. Lee, executive vice president of Chemed(CHE -0.88%), sold 1,000 shares of stock on Aug. 21, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $541,040 |
| Shares sold | 1,000 |
| Post-transaction shares (directly held) | 13,912 |
| Post-transaction value | $7.5 million |
Transaction value based on SEC Form 4 weighted average sale price ($541.04); post-transaction value based on Aug. 21, 2026, market close ($540.57).
Key questions
- How significant was the transaction relative to the executive’s total equity position?
The sale of 1,000 shares represents a 7% reduction in Lee’s direct holdings. The remaining stake is valued at approximately $7.5 million based on the Aug. 21, 2026, market close of $540.57. - At what valuation did the executive execute the sale?
The shares were sold at $541.04 per share, while the stock was priced at $540.57 at the market close on Aug. 21, 2026. On the date of the transaction, the stock’s one-year return was 19% as of the Aug. 21, 2026, market close. - What is the current scale of the company’s operations and market presence?
Chemed, headquartered in Cincinnati, employs 15,811 people and has a market capitalization of $6.7 billion. The company provides hospice care and various residential and commercial plumbing and restoration services. - What is the composition of the executive’s remaining ownership?
The executive’s equity position is held entirely through direct ownership, representing a 0.1% ownership interest in the company. No indirect holdings in trusts or other legal entities were reported in this transaction.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-21) | $540.57 |
| Market Capitalization | $6.7 billion |
| Revenue (TTM) | $2.6 billion |
| Net Income (TTM) | $275 million |
Company Snapshot
- Chemed provides hospice and palliative care services through a network of physicians, nurses, home health aides, and support personnel, and Roto-Rooter, which delivers plumbing, drain cleaning, excavation, water restoration, and related services to residential and commercial customers.
- The company generates revenue through recurring service delivery models in both healthcare and home services sectors, leveraging company-owned branches and independent contractor networks to serve patients and customers across the United States.
- Chemed’s primary customer base consists of patients requiring end-of-life and palliative care services, as well as residential and commercial property owners requiring plumbing and water restoration services, positioning the company across essential healthcare and home maintenance markets.
Chemed is a diversified healthcare and services company with a $6.7 billion market capitalization, operating a substantial network of 15,811 employees across two complementary business segments. The company’s dual-segment strategy combines high-margin hospice and palliative care services with established home services operations, generating $2.6 billion in TTM revenue and $275 million in net income. This diversified approach provides revenue stability while capitalizing on secular trends in aging demographics and rising demand for essential home services.
Today’s Change
(-0.88%) $-4.61
Current Price
$519.84
Key Data Points
Market Cap
Day’s Range
$519.23 – $525.63
52wk Range
$365.20 – $557.00
Volume
84.3K
Avg Vol
180.3K
Gross Margin
30.44%
Dividend Yield
0.48%
What this transaction means for investors
As of this writing, the Chemed stock price has performed well in 2026, climbing 21.5%. In comparison, it’s outperforming the S&P 500, which has climbed 12.7% over the same period. With that context, Lee’s transaction doesn’t appear to indicate that anything is amiss with the company, as it appears to be just a routine sale. While the insider sold 1,000 shares, he still holds nearly 14,000 shares.
That said, analysts are a little cautious about what’s ahead for the Chemed stock price over the next year. Of the five analysts who cover the stock, 20% rate it as a buy, 60% as a hold, and the other 20% as a sell. The median price target for the stock over the next 12 months from that group is $549, representing a potential gain of only 5.6% from the current price ($519.84). The highest price target, $590, suggests a bit more upside, representing a 13.5% gain. The lowest price target, however, of $520, suggests the stock could trade flat over the next 12 months.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
